Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0S5FF
|
|||
| Former ID |
DNCL003651
|
|||
| Drug Name |
BYM338
|
|||
| Indication | Inclusion body myositis [ICD-11: 4A41.2; ICD-10: G72.8] | Phase 3 | [1] | |
| Acute myeloid leukaemia [ICD-11: 2A60] | Phase 2/3 | [2], [3] | ||
| Muscle atrophy [ICD-11: FB32.Y; ICD-9: 728.2] | Phase 2 | [4] | ||
| Company |
Novartis
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Activin receptor type IIA (ACVR2A) | Target Info | Inhibitor | [4] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8086). | |||
| REF 3 | ClinicalTrials.gov (NCT02573467) An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203. | |||
| REF 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.